Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
MMED heads into its October 9 earnings report with one of the most constrained borrow markets on Nasdaq and a short position that has nearly tripled in six weeks.
The lending market tells the starkest part of the setup. Availability has collapsed to just 0.38%, the lowest reading of the past year, meaning there is effectively one share left to borrow for every 263 already lent out. That tightness arrived fast: six weeks ago, availability was above 50% and cost to borrow was near 4%. Cost to borrow has since more than doubled in a week, reaching 19.2%, and short interest itself has risen 219% over the past month to roughly 22.8 million shares. The ORTEX short score sits at 89.9, near the top of the range it has held since late September, reflecting a broad alignment of bearish lending signals. Yet options positioning is moving in the opposite direction. The put/call ratio has fallen sharply to 0.86, well below its 20-day average of 1.15 and about 1.2 standard deviations beneath that average, meaning options traders have actually rotated toward calls heading into the print. That divergence is the central tension: the borrow market is maximally squeezed while options positioning has turned more bullish than usual.
The bull and bear cases are well defined by the analyst community, which remains constructive on balance. After the September 1 print, nearly every covering firm raised its target, with Morgan Stanley, Citi, Evercore, Wells Fargo, UBS, Mizuho, and BofA all lifting numbers. Truist then initiated with a Buy and a $29 target on September 24, the most recent action. The mean target is $24.69, implying roughly 26% upside from the current price of $19.64. Bulls focus on MiniMed's standalone operating model, its end-to-end automated insulin delivery stack, and a pharmacy channel and Abbott CGM partnership that together create a differentiated position in an underpenetrated diabetes market. New launches, including Flex, Fit, Go, and Vivera, are modeled to push revenue from $3.1 billion in FY26 toward $4.1 billion by FY29. Bears counter that nearly 90% of shares remain tied to Medtronic's eventual tax-free distribution, limiting genuine price discovery, while delayed launches, pharmacy price pressure, and GLP-1 uncertainty add execution risk at a point where stand-up costs still weigh on margins.
The ownership structure reinforces the bear case's structural concern. Medtronic holds 89.9% of shares via a Schedule 13G passive filing dated May 2026, leaving only a thin publicly traded float. That constraint directly explains the severity of the borrow squeeze: short sellers are competing for a small pool of lendable shares. Among institutional owners beyond Medtronic, MFS added 1.46 million shares as of June 30, Norges Bank built a fresh position of 1.96 million shares, and BlackRock added 1.97 million shares as of September 30, suggesting some institutions are positioning constructively despite the overhang. The stock's own earnings history offers a reference point: the last two prints produced one-day gains of roughly 14% and 17% respectively, with five-day gains of similar magnitude both times.
The print on Thursday will test whether the strong analyst consensus and bullish options tilt can be validated by the numbers, or whether the crowded short position, exhausted borrow, and unresolved Medtronic overhang represent a better read of near-term risk.
See the live data behind this article on ORTEX.
Open MMED on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
